| Literature DB >> 29965787 |
Artur Jurczyszyn1, Jorge J Castillo2, Irit Avivi3, Jacek Czepiel4, Julio Davila5, Ravi Vij6, Mark A Fiala6, Alessandro Gozzetti7, Norbert Grząśko8,9, Vibor Milunovic10, Iwona Hus11, Krzysztof Mądry12, Anna Waszczuk-Gajda12, Lidia Usnarska-Zubkiewicz13, Jakub Dębski13, Erden Atilla14, Meral Beksac14, Giuseppe Mele15, Waldemar Sawicki16, David Jayabalan17, Grzegorz Charliński18, Agoston Gyula Szabo19, Roman Hajek20, Michel Delforge21, Agnieszka Kopacz22, Dorotea Fantl23, Anders Waage24, Edvan Crusoe25, Vania Hungria25, Paul Richardson2, Jacob Laubach2, Thomas Guerrero-Garcia26, Jieqi Liu27, David H Vesole28.
Abstract
This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count ≤100 × 109/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.Entities:
Keywords: Autologous stem cell transplantation; proteasome inhibitors; secondary plasma cell leukemia
Mesh：
Substances：
Year: 2018 PMID： 29965787 DOI： 10.1080/10428194.2018.1473574
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022